Wilkes University NSG 533 Advanced Pharmacology Exam 2
Prep | 2026/2027 Edition | 150 Verified Questions - 130
Questions with Answers
NSG 533 Advanced Pharmacology Exam 2 2026-130 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document for Wilkes University's NSG 533 Advanced
Pharmacology course focuses on the second exam, covering 150 verified questions. It provides detailed
rationales for each answer, emphasizing clinical application and evidence-based prescribing. The
content is aligned with the latest 2026-2027 academic guidelines and is designed to reinforce advanced
pharmacotherapeutic concepts. Ideal for graduate nursing students seeking a thorough review and high
achievement on the exam.
Key Features:
Pharmacokinetics and pharmacodynamics of major drug classes
Evidence-based prescribing for common chronic conditions
Management of adverse drug reactions and drug interactions
Special population considerations (pediatric, geriatric, pregnancy)
Clinical decision-making and patient education strategies
Updated per 2026-2027 guidelines and standards
Updates for 2026:
- Revised to include the latest FDA approvals and black box warnings
- Updated drug interaction tables and contraindication lists
- Enhanced rationales with current clinical practice guidelines
- Added new questions on recently approved biologics and targeted therapies
- Aligned with the 2026-2027 academic year curriculum updates
Abstract:
This exam preparation document is meticulously crafted for graduate nursing students enrolled in Wilkes
University's NSG 533 Advanced Pharmacology course, specifically targeting Exam 2. It comprises 150 verified
questions that span a broad spectrum of advanced pharmacological principles, including drug classifications,
mechanisms of action, therapeutic uses, adverse effects, and clinically significant interactions. Each question is
accompanied by a comprehensive rationale that not only explains the correct answer but also analyzes why
alternative choices are incorrect, thereby deepening the student's understanding. The content is updated to reflect
the latest evidence-based practices and regulatory guidelines as of the 2026-2027 academic year. Emphasis is
placed on the application of pharmacological knowledge in clinical scenarios, particularly for managing patients
with complex health conditions. This resource is an invaluable tool for students aiming to excel in their exam and,
ultimately, in their advanced nursing practice.
Keywords:
Advanced Pharmacology, NSG 533, Exam 2, Nursing Pharmacology, Drug Interactions, Pharmacotherapeutics,
Clinical Decision-Making, Graduate Nursing
Answer Format:
Each question is presented in multiple-choice format with four options. The correct answer is clearly indicated,
followed by a detailed rationale explaining the pharmacological basis and clinical reasoning. Additionally, each
incorrect option is analyzed to clarify why it is not the best choice, enhancing critical thinking and application.
Page 1
,Compliance Checklist:
All questions are verified and aligned with the 2026-2027 curriculum
Rationales are evidence-based and reference current guidelines
Content covers all major drug classes and their clinical applications
Special population considerations are included where applicable
Drug interactions and adverse effects are thoroughly addressed
Questions reflect the exam format and difficulty level
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-30 Absorption, distribution, metabolism, 20%
Pharmacodynamics excretion; receptor theory; dose-response
relationships
Cardiovascular Pharmacology 31-60 Antihypertensives, antiarrhythmics, 20%
anticoagulants, lipid-lowering agents
Endocrine Pharmacology 61-90 Insulin and oral hypoglycemics, thyroid 20%
medications, corticosteroids
Neurological and Psychiatric 91-120 Antiepileptics, antidepressants, 20%
Pharmacology antipsychotics, anxiolytics
Antimicrobial and Analgesic 121-150 Antibiotics, antivirals, opioids, NSAIDs 20%
Pharmacology
Page 2
,Q1. A patient on warfarin with a therapeutic INR of 2.5 is prescribed a course of
trimethoprim-sulfamethoxazole for a urinary tract infection. Three days later, the
INR is 5.8. Which pharmacodynamic mechanism best explains this interaction?
A. Inhibition of CYP2C9 by trimethoprim, reducing warfarin metabolism
B. Displacement of warfarin from plasma protein binding sites by sulfamethoxazole
C. Additive inhibition of vitamin K epoxide reductase by both drugs
D. Reduced gut flora synthesis of vitamin K due to antibiotic therapy
Correct Answer: A. Inhibition of CYP2C9 by trimethoprim, reducing warfarin
metabolism
Rationale: Trimethoprim-sulfamethoxazole inhibits CYP2C9, the primary enzyme
metabolizing the S-enantiomer of warfarin, leading to increased warfarin levels and INR.
While sulfamethoxazole can displace warfarin from protein binding, this effect is transient
and not the primary cause of a sustained INR elevation. Reduced vitamin K synthesis
contributes but is less significant than CYP inhibition.
Why Wrong:
B - Protein binding displacement is transient and not the main mechanism for a
significant, sustained INR increase.
C - Warfarin itself inhibits vitamin K epoxide reductase; the antibiotic does not add to
this effect directly.
D - Antibiotic-induced reduction in gut flora vitamin K synthesis is a minor
contributor compared to CYP2C9 inhibition.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 85
Q2. A patient with chronic heart failure is on digoxin, furosemide, and lisinopril.
Recently, the patient started taking a proton pump inhibitor (PPI) for
gastroesophageal reflux. Which change in laboratory values would be most
concerning for digoxin toxicity?
A. Serum potassium of 3.2 mEq/L
B. Serum creatinine of 1.8 mg/dL
C. Serum magnesium of 2.0 mEq/L
D. Serum calcium of 9.5 mg/dL
Correct Answer: A. Serum potassium of 3.2 mEq/L
Rationale: Hypokalemia (K+ <3.5 mEq/L) increases the risk of digoxin toxicity by
enhancing digoxin binding to Na+/K+-ATPase in cardiac muscle. Furosemide can cause
hypokalemia, and PPIs may contribute to hypomagnesemia, but the direct effect of
hypokalemia on digoxin toxicity is well-established. Elevated creatinine may reduce
digoxin clearance, but the question asks for the most concerning change; hypokalemia is a
classic precipitant.
Page 3
, Why Wrong:
B - Renal impairment affects digoxin clearance, but the specific change in potassium
is more directly related to digoxin toxicity risk.
C - Magnesium of 2.0 mEq/L is within normal range; hypomagnesemia (not
hypermagnesemia) increases digoxin toxicity risk.
D - Calcium of 9.5 mg/dL is normal; hypercalcemia can increase digoxin toxicity but
this value is not elevated.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 47
Q3. A patient with type 2 diabetes and chronic kidney disease (eGFR 35
mL/min/1.73m²) is being initiated on an SGLT2 inhibitor. Which of the following
statements best reflects the current evidence and guideline recommendations?
A. SGLT2 inhibitors are contraindicated at eGFR below 45 mL/min/1.73m².
B. SGLT2 inhibitors are not recommended because they increase the risk of
hypoglycemia.
C. SGLT2 inhibitors are preferred in this population due to cardiovascular and renal
benefits, but may have reduced glycemic efficacy at lower eGFR.
D. SGLT2 inhibitors should be avoided because they cause hyperkalemia and worsen
renal function.
Correct Answer: C. SGLT2 inhibitors are preferred in this population due to
cardiovascular and renal benefits, but may have reduced glycemic efficacy at lower
eGFR.
Rationale: Current guidelines (ADA, KDIGO) recommend SGLT2 inhibitors for patients
with type 2 diabetes and CKD (eGFR 25 mL/min/1.73m²) due to their cardiovascular and
renal protective effects. While glycemic efficacy diminishes at lower eGFR, the benefits
persist, and they are not contraindicated until eGFR <25. They do not cause hyperkalemia
and have low intrinsic hypoglycemia risk.
Why Wrong:
A - Contraindication threshold is eGFR <25, not <45; many agents can be used down
to 30.
B - SGLT2 inhibitors have a low risk of hypoglycemia; they do not increase it
significantly.
D - SGLT2 inhibitors do not cause hyperkalemia; they may cause initial dip in eGFR
but not worsen renal function long-term.
Reference: ADA Standards of Medical Care in Diabetes-2026, Ch. 9
Q4. A patient is receiving vancomycin 1 g IV every 12 hours. The trough level is 25
mcg/mL. Which of the following actions is most appropriate based on the 2020
vancomycin consensus guidelines?
A. Continue the current dose; trough of 25 is within the target for severe infections.
Page 4
Prep | 2026/2027 Edition | 150 Verified Questions - 130
Questions with Answers
NSG 533 Advanced Pharmacology Exam 2 2026-130 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document for Wilkes University's NSG 533 Advanced
Pharmacology course focuses on the second exam, covering 150 verified questions. It provides detailed
rationales for each answer, emphasizing clinical application and evidence-based prescribing. The
content is aligned with the latest 2026-2027 academic guidelines and is designed to reinforce advanced
pharmacotherapeutic concepts. Ideal for graduate nursing students seeking a thorough review and high
achievement on the exam.
Key Features:
Pharmacokinetics and pharmacodynamics of major drug classes
Evidence-based prescribing for common chronic conditions
Management of adverse drug reactions and drug interactions
Special population considerations (pediatric, geriatric, pregnancy)
Clinical decision-making and patient education strategies
Updated per 2026-2027 guidelines and standards
Updates for 2026:
- Revised to include the latest FDA approvals and black box warnings
- Updated drug interaction tables and contraindication lists
- Enhanced rationales with current clinical practice guidelines
- Added new questions on recently approved biologics and targeted therapies
- Aligned with the 2026-2027 academic year curriculum updates
Abstract:
This exam preparation document is meticulously crafted for graduate nursing students enrolled in Wilkes
University's NSG 533 Advanced Pharmacology course, specifically targeting Exam 2. It comprises 150 verified
questions that span a broad spectrum of advanced pharmacological principles, including drug classifications,
mechanisms of action, therapeutic uses, adverse effects, and clinically significant interactions. Each question is
accompanied by a comprehensive rationale that not only explains the correct answer but also analyzes why
alternative choices are incorrect, thereby deepening the student's understanding. The content is updated to reflect
the latest evidence-based practices and regulatory guidelines as of the 2026-2027 academic year. Emphasis is
placed on the application of pharmacological knowledge in clinical scenarios, particularly for managing patients
with complex health conditions. This resource is an invaluable tool for students aiming to excel in their exam and,
ultimately, in their advanced nursing practice.
Keywords:
Advanced Pharmacology, NSG 533, Exam 2, Nursing Pharmacology, Drug Interactions, Pharmacotherapeutics,
Clinical Decision-Making, Graduate Nursing
Answer Format:
Each question is presented in multiple-choice format with four options. The correct answer is clearly indicated,
followed by a detailed rationale explaining the pharmacological basis and clinical reasoning. Additionally, each
incorrect option is analyzed to clarify why it is not the best choice, enhancing critical thinking and application.
Page 1
,Compliance Checklist:
All questions are verified and aligned with the 2026-2027 curriculum
Rationales are evidence-based and reference current guidelines
Content covers all major drug classes and their clinical applications
Special population considerations are included where applicable
Drug interactions and adverse effects are thoroughly addressed
Questions reflect the exam format and difficulty level
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-30 Absorption, distribution, metabolism, 20%
Pharmacodynamics excretion; receptor theory; dose-response
relationships
Cardiovascular Pharmacology 31-60 Antihypertensives, antiarrhythmics, 20%
anticoagulants, lipid-lowering agents
Endocrine Pharmacology 61-90 Insulin and oral hypoglycemics, thyroid 20%
medications, corticosteroids
Neurological and Psychiatric 91-120 Antiepileptics, antidepressants, 20%
Pharmacology antipsychotics, anxiolytics
Antimicrobial and Analgesic 121-150 Antibiotics, antivirals, opioids, NSAIDs 20%
Pharmacology
Page 2
,Q1. A patient on warfarin with a therapeutic INR of 2.5 is prescribed a course of
trimethoprim-sulfamethoxazole for a urinary tract infection. Three days later, the
INR is 5.8. Which pharmacodynamic mechanism best explains this interaction?
A. Inhibition of CYP2C9 by trimethoprim, reducing warfarin metabolism
B. Displacement of warfarin from plasma protein binding sites by sulfamethoxazole
C. Additive inhibition of vitamin K epoxide reductase by both drugs
D. Reduced gut flora synthesis of vitamin K due to antibiotic therapy
Correct Answer: A. Inhibition of CYP2C9 by trimethoprim, reducing warfarin
metabolism
Rationale: Trimethoprim-sulfamethoxazole inhibits CYP2C9, the primary enzyme
metabolizing the S-enantiomer of warfarin, leading to increased warfarin levels and INR.
While sulfamethoxazole can displace warfarin from protein binding, this effect is transient
and not the primary cause of a sustained INR elevation. Reduced vitamin K synthesis
contributes but is less significant than CYP inhibition.
Why Wrong:
B - Protein binding displacement is transient and not the main mechanism for a
significant, sustained INR increase.
C - Warfarin itself inhibits vitamin K epoxide reductase; the antibiotic does not add to
this effect directly.
D - Antibiotic-induced reduction in gut flora vitamin K synthesis is a minor
contributor compared to CYP2C9 inhibition.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 85
Q2. A patient with chronic heart failure is on digoxin, furosemide, and lisinopril.
Recently, the patient started taking a proton pump inhibitor (PPI) for
gastroesophageal reflux. Which change in laboratory values would be most
concerning for digoxin toxicity?
A. Serum potassium of 3.2 mEq/L
B. Serum creatinine of 1.8 mg/dL
C. Serum magnesium of 2.0 mEq/L
D. Serum calcium of 9.5 mg/dL
Correct Answer: A. Serum potassium of 3.2 mEq/L
Rationale: Hypokalemia (K+ <3.5 mEq/L) increases the risk of digoxin toxicity by
enhancing digoxin binding to Na+/K+-ATPase in cardiac muscle. Furosemide can cause
hypokalemia, and PPIs may contribute to hypomagnesemia, but the direct effect of
hypokalemia on digoxin toxicity is well-established. Elevated creatinine may reduce
digoxin clearance, but the question asks for the most concerning change; hypokalemia is a
classic precipitant.
Page 3
, Why Wrong:
B - Renal impairment affects digoxin clearance, but the specific change in potassium
is more directly related to digoxin toxicity risk.
C - Magnesium of 2.0 mEq/L is within normal range; hypomagnesemia (not
hypermagnesemia) increases digoxin toxicity risk.
D - Calcium of 9.5 mg/dL is normal; hypercalcemia can increase digoxin toxicity but
this value is not elevated.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 47
Q3. A patient with type 2 diabetes and chronic kidney disease (eGFR 35
mL/min/1.73m²) is being initiated on an SGLT2 inhibitor. Which of the following
statements best reflects the current evidence and guideline recommendations?
A. SGLT2 inhibitors are contraindicated at eGFR below 45 mL/min/1.73m².
B. SGLT2 inhibitors are not recommended because they increase the risk of
hypoglycemia.
C. SGLT2 inhibitors are preferred in this population due to cardiovascular and renal
benefits, but may have reduced glycemic efficacy at lower eGFR.
D. SGLT2 inhibitors should be avoided because they cause hyperkalemia and worsen
renal function.
Correct Answer: C. SGLT2 inhibitors are preferred in this population due to
cardiovascular and renal benefits, but may have reduced glycemic efficacy at lower
eGFR.
Rationale: Current guidelines (ADA, KDIGO) recommend SGLT2 inhibitors for patients
with type 2 diabetes and CKD (eGFR 25 mL/min/1.73m²) due to their cardiovascular and
renal protective effects. While glycemic efficacy diminishes at lower eGFR, the benefits
persist, and they are not contraindicated until eGFR <25. They do not cause hyperkalemia
and have low intrinsic hypoglycemia risk.
Why Wrong:
A - Contraindication threshold is eGFR <25, not <45; many agents can be used down
to 30.
B - SGLT2 inhibitors have a low risk of hypoglycemia; they do not increase it
significantly.
D - SGLT2 inhibitors do not cause hyperkalemia; they may cause initial dip in eGFR
but not worsen renal function long-term.
Reference: ADA Standards of Medical Care in Diabetes-2026, Ch. 9
Q4. A patient is receiving vancomycin 1 g IV every 12 hours. The trough level is 25
mcg/mL. Which of the following actions is most appropriate based on the 2020
vancomycin consensus guidelines?
A. Continue the current dose; trough of 25 is within the target for severe infections.
Page 4
